Qiagen (NYSE:QGEN) Price Target Raised to $50.00 at JPMorgan Chase & Co.

Qiagen (NYSE:QGEN) had its target price hoisted by equities research analysts at JPMorgan Chase & Co. from $45.00 to $50.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 17.76% from the stock’s current price.

A number of other analysts have also recently weighed in on the stock. Jefferies Financial Group reaffirmed a “buy” rating and set a $48.00 target price on shares of Qiagen in a research note on Thursday. Kepler Capital Markets set a $38.60 price target on Qiagen and gave the company a “hold” rating in a research note on Thursday, June 25th. Berenberg Bank set a $45.50 price objective on Qiagen and gave the company a “hold” rating in a report on Tuesday, July 14th. TD Cowen restated a “hold” rating on shares of Qiagen in a research report on Wednesday, July 15th. Finally, Barclays set a $40.00 target price on Qiagen in a report on Friday. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Qiagen has an average rating of “Hold” and a consensus price target of $43.34.

Qiagen Price Performance

NYSE QGEN traded up $0.73 during trading on Friday, hitting $42.46. 1,204,113 shares of the company’s stock were exchanged, compared to its average volume of 2,433,088. The company has a market cap of $8.75 billion, a PE ratio of 21.76, a P/E/G ratio of 4.19 and a beta of 0.63. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49. Qiagen has a fifty-two week low of $32.53 and a fifty-two week high of $57.81. The stock’s 50 day moving average price is $39.32 and its two-hundred day moving average price is $41.69.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.60 by $0.02. The company had revenue of $535.04 million for the quarter, compared to the consensus estimate of $527.50 million. Qiagen had a net margin of 19.49% and a return on equity of 14.24%. The firm’s quarterly revenue was up .2% compared to the same quarter last year. During the same period last year, the company posted $0.60 EPS. Qiagen has set its FY 2026 guidance at 2.430- EPS. Research analysts expect that Qiagen will post 2.43 EPS for the current year.

Institutional Investors Weigh In On Qiagen

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Danske Bank A S bought a new stake in Qiagen in the third quarter valued at approximately $36,000. Manchester Capital Management LLC acquired a new stake in shares of Qiagen during the fourth quarter worth $42,000. Hilltop National Bank acquired a new position in Qiagen in the second quarter valued at $50,000. Global Retirement Partners LLC grew its holdings in Qiagen by 279.9% during the 4th quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock worth $52,000 after acquiring an additional 851 shares during the period. Finally, Advisory Services Network LLC bought a new position in shares of Qiagen in the 3rd quarter worth about $64,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.